Risk minimisation materials for Filgotinib (Jyseleca)
A healthcare professional guide contains information on risks of treatment which should be considered and discussed when prescribing, including infection, birth defects, effects on male fertility, potential risks of venous thromboembolism and major adverse CV events.
Source:
electronic Medicines compendium
SPS commentary:
Prescribers should provide a Patient Alert Card to anyone started on treatment with filgotinib, and explain to them that it contains important information that they should be aware of before, during and after treatment. They should read this alongside the Patient Information Leaflet, and show it to anyone involved in their care or treatment.